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We recently identified hypermethylation at the gene promoter of transcrip-
tion factor 21 (TCF21) in clear cell sarcoma of the kidney (CCSK), a rare
pediatric renal tumor. TCF21 is a transcription factor involved in tubular
epithelial development of the kidney and is a candidate tumor suppressor.
As there are no in vitro models of CCSK, we employed a well-established
clear cell renal cell carcinoma (ccRCC) cell line, 786-O, which also mani-
fests high methylation at the TCF21 promoter, with consequent low
TCF21 expression. The tumor suppressor function of TCF21 has not been
functionally addressed in ccRCC cells; we aimed to explore the functional
potential of TCF21 expression in ccRCC cells in vitro. 786-O clones stably
transfected with either pBABE-TCF21-HA construct or pBABE vector
alone were functionally analyzed. We found that ectopic expression of
TCF21 in 786-O cells results in a trend toward decreased cell proliferation
(not significant) and significantly decreased migration compared with
mock-transfected 786-O cells. Although the number of colonies established
in colony formation assays was not different between 786-O clones, colony
size was significantly reduced in 786-O cells expressing TCF21. To investi-
gate whether the changes in migration were due to epithelial-to-mesenchy-
mal transition changes, we interrogated the expression of selected epithelial
and mesenchymal markers. Although we observed upregulation of mRNA
and protein levels of epithelial marker E-cadherin in clones overexpressing
TCF21, this did not result in surface expression of E-cadherin as measured
by fluorescence-activated cell sorting and immunofluorescence. Further-
more, mRNA expression of the mesenchymal markers vimentin (VIM) and
SNAI1 was not significantly decreased in TCF21-expressing 786-O cells,
while protein levels of VIM were markedly decreased. We conclude that re-
expression of TCF21 in renal cancer cells that have silenced their endoge-
nous TCF21 locus through hypermethylation results in reduced clonogenic
proliferation, reduced migration, and reduced mesenchymal-like character-
istics, suggesting a tumor suppressor function for transcription factor 21.
Abbreviations
CCSK, clear cell sarcoma of the kidney; EMT, epithelial-to-mesenchymal transition; FACS, fluorescence-activated cell sorting; MET,
mesenchymal-to-epithelial transition; MFI, median fluorescence intensity; RCC, renal cell carcinoma; TARGET, therapeutically applicable
research to generate effective treatments; TCF21, transcription factor 21.
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1. Introduction
Clear cell sarcoma of the kidney (CCSK) is an uncom-
mon pediatric renal tumor that comprises between 2%
and 5% of all primary renal tumors in children (Furt-
wangler et al., 2013; Gooskens et al., 2012; Mullen
et al., 2014). This tumor is observed most often in chil-
dren between 2 and 4 years of age and is characterized
by a high malignant potential (Argani et al., 2000;
Gooskens et al., 2012). Apart from internal tandem
duplications within exon 16 of BCOR (reported in the
majority of CCSKs) and translocation t(10;17)(q22;p13)
leading to a fusion of YWHAE and NUTM2B/E (re-
ported in about 10% of CCSKs), the genome of CCSK
seems to be rather stable (Astolfi et al., 2015; Gooskens
et al., 2015; Karlsson et al., 2015; Roy et al., 2015;
Ueno-Yokohata et al., 2015). This paucity of large
genomic imbalances and the few detected somatic muta-
tions in CCSK prompted the investigation of the epigen-
ome of CCSKs. Our study as part of the NCI-initiated
therapeutically applicable research to generate effective
treatment project (TARGET) identified hypermethyla-
tion of the 50 region of transcription factor 21 (TCF21)
in all studied CCSK samples, except for samples harbor-
ing the YWHAE-NUTM2 fusion transcript (Gooskens
et al., 2015). This hypermethylation was negatively cor-
related with TCF21 expression. Other tested pediatric
renal tumor samples and normal kidney samples showed
significantly lower TCF21methylation levels.
TCF21 (also referred to as Pod-1, capsulin, and epi-
cardin) encodes a basic helix-loop-helix transcription
factor that binds DNA and regulates cell differentia-
tion and cell-fate specification during development
(Hidai et al., 1998). It is expressed in embryonic mes-
enchymal cells surrounding areas of epithelial develop-
ment in the kidney, heart, lung, and gastrointestinal
tract (Hidai et al., 1998; Lu et al., 1998; Quaggin
et al., 1998). TCF21 expression rapidly decreases in
postnatal tissues with the exception of a subset of
interstitial cells in organs including the kidney, heart,
lung, and spleen (Plotkin and Mudunuri, 2008). Anti-
sense inhibition of TCF21 has been reported to disrupt
epithelial differentiation and branching morphogenesis
of the epithelium in murine embryonic kidney, suggest-
ing a role for TCF21 in epithelial–mesenchymal inter-
actions (Quaggin et al., 1999). Gene deletion studies in
chimeric mice have shown that loss of TCF21 in the
kidney results in decreased glomerulogenesis and tubu-
logenesis (Cui et al., 2003). Of note, suppression of
TCF21 expression by siRNA within a mouse kidney
progenitor cell line that endogenously expresses TCF21
resulted in increased cell proliferation and migration,
as well as reduced expression of smooth muscle genes
and myofibroblast secreted proteins (Plotkin and
Mudunuri, 2008).
Currently, no CCSK cell lines or models are available
to functionally verify the role of TCF21 hypermethylation
in this renal tumor type. Therefore, we searched for an
alternative model. A literature search revealed that
TCF21 hypermethylation is also present in clear cell renal
cell carcinomas (ccRCC): renal tumors with another biol-
ogy and phenotype, which most often occur in adults
(Costa et al., 2011; Ye et al., 2012). Previously performed
clinical studies on the prognostic impact of TCF21 expres-
sion in ccRCC tissue revealed that TCF21 expression
levels significantly correlated with Fuhrman nuclear grade
and cancer-specific survival of ccRCC patients (Ye et al.,
2012). TCF21 methylation levels in urine samples were
significantly correlated with tumor size, Fuhrman grade,
and clinical stage (Xin et al., 2016). However, no studies
have functionally addressed the tumor suppressor activity
of TCF21 in renal cancer cells. Therefore, the aim of this
study was to explore the functional potential of TCF21
expression in the tumorigenesis of ccRCC in vitro.
2. Methods
2.1. Cancer cell lines
We used the human ccRCC 786-O cell line (ATCC
CRL-1932). 786-O cells are reported to manifest high
methylation and low expression of TCF21 (Costa
et al., 2011). Cells were cultured in Gibco RPMI Med-
ium 1640 (1X) + GlutaMAXTM-I (Invitrogen, Carls-
bad, CA, USA), supplemented with 10% fetal bovine
serum (Invitrogen), penicillin (50 IUmL1), and strep-
tomycin sulfate (50 lgmL1; Invitrogen).
2.2. Vector construction and transfection
The coding sequence of TCF21 (including HA-tag)
was cloned out of a pCS2+-TCF21 construct [kindly
provided by Prof. Christopher Plass and Khalifa Arab,
Division of Epigenomics and Cancer Risk Factors,
German Cancer Research Center (DKFZ), Heidelberg,
Germany], amplified, and recloned into a pBABE-puro
vector. Plasmid DNAs were sequence-confirmed.
Twenty-five micrograms of pBABE-TCF21-HA or
pBABE-puro vector alone was transfected into cells of
the 786-O cell line using electroporation. Electropora-
tion was performed in a 4-mm gap cuvette (#165-2088;
Bio-Rad Laboratories, Hercules, CA, USA) using a
Gene Pulser (Bio-Rad, M€unchen, Germany) with elec-
tric parameters 24 kV with 1000 uF capacitance; a sin-
gle exponential decay pulse was applied. Selection
medium containing puromycin was added to the cells
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after 48 h of recovery, and colonies grew after 2 weeks
of culture. Eight colonies were selected for functional
assays: four from pBABE-puro mock-transfected 786-
O cells (N1F4, B5F1, N1G4, and B6D10) and four
expressing HA-tagged exogenous TCF21 (2B12, 5D2,
9D12, and 9H9). Unless the clones are specifically
named, data from ‘pBABE-mock’ or ‘pBABE-TCF21’
contain pooled data from all four clones.
2.3. Western blotting
Cells were lysed on ice in RIPA buffer and normalized
to 40 lg of protein per sample. Lysates were loaded and
fractionated by SDS/PAGE (14% gel) under protein-
reducing conditions and immunoblotted on poly(vinyli-
dene difluoride) (PVDF) membranes. b-Actin or b-tubu-
lin was used as loading control. After blotting, the
PVDF membranes were blocked in 5% dried skim
milk in TBS with 0.5% Tween. Primary antibodies
used were monoclonal mouse anti-HA (supernatant
from hybridoma clone 12CA5) at a dilution of 1 : 3,
rabbit polyclonal anti-TCF21 (32981, 1 : 10 000;
Abcam, Cambridge, UK), rabbit polyclonal anti-E-cad-
herin (15148, 1 : 500; Abcam), rabbit anti-VIM (VIM;
R28; 3932, 1 : 200; Cell Signaling, Danvers, MA, USA)
with loading controls being anti-actin (mouse anti-b-
actin AC-15, Sigma A5441, 1∶15 000) or anti-b-tubulin
(rabbit anti-b-tubulin Cat. 2128, 1 : 1000; Cell Signal-
ing). ECL reagent (Amersham Biosciences) was used for
detection with ImageQuant LAS 4000 (GE Healthcare,
Hoevelaken, the Netherlands).
2.4. Proliferation assay
A total of 2 9 104 786-O pBABE-mock cells (four dif-
ferent clones) and 786-O pBABE-TCF21 cells (four dif-
ferent clones) were plated in 6-well plates in two
separate experiments in triplicate in selection medium
and were counted after 2, 4, and 5 days. Cells were
counted in duplicate with the Bio-Rad TC20 Automated
Cell Counter (Hercules, CA, USA) and averaged.
2.5. Colony formation assay
A total of 200 786-O pBABE-mock cells (four differ-
ent clones) and 786-O pBABE-TCF21 cells (four dif-
ferent clones) were plated in 6-well plates on five
different occasions in triplicate in selection medium
until 786-O pBABE-mock cells formed sufficiently
large colonies (> 50 cells per colony, 10–14 days). Cells
were then washed with PBS and fixed and stained
using a mixture of 6.0% glutaraldehyde and 0.5%
crystal violet for 30 min at room temperature, before
being washed in water. Wells were individually pho-
tographed and analyzed by the Colony Counter plug-
in for Image J software. Numbers of colonies and col-
ony area were calculated in Image J.
2.6. Migration assays
Boyden chambers (Transwell Permeable Supports;
Cole-Parmer; BergmanLabora AB, Danderyd, Sweden)
were used to evaluate the migratory capacity of 786-O
pBABE-mock cells (N1G4 and B6D10 clones) and 786-
O pBABE-TCF21 cells (9D12 and 5D2 clones). 3 9 104
cells were seeded in the upper section of a Boyden cham-
ber containing serum-free medium. The lower section,
separated from the upper one by a membrane with 8-lm
pores, contained medium with 10% serum. Cells were
grown at 37 °C for 16 h, fixed in methanol, and stained
with DAPI (1 : 2000). Unmigrated cells on top of the
membrane were removed with a cotton tip. The number
of migrated cells on the bottom of the membrane was
evaluated by counting cells in 10 different views per
membrane using microscopy at 109 magnification. The
experiments were performed in duplicate and were
repeated two times (first time N1G4/B6D10 versus
9D12/5D2, second time N1G4 versus 5D2).
For the real-time migration assay, in each experiment,
a modified Boyden chamber setup was used, with 10%
serum in the lower well as chemoattractant. Migration
was recorded in real-time at 5-min intervals over 24 h
using the xCELLigence Real-Time Cell Analysis system
(Acea Biosciences, San Diego, CA, USA), which quanti-
fies cell numbers in the lower compartment by electrical
impedance as reported by Gremmels et al. (2014). Rate
of migration was quantified by calculating a series of
moving slopes over 12 interval periods and taking the
maximum slope in each migration curve. The moving
slope takes the slope over small sections of the S-curve,
12 intervals of 5 min. So one takes the slope over the 0-
to 60-min interval, 5- to 65-min, 10- to 70-min, 15- to
75-min interval, and so on until the last point. Of the
values, the highest value is the maximum slope for a
given curve, which we used for analysis.
Within each experiment, four technical replicates per
clone were recorded and the experiment was repeated
on three separate days. Data were analyzed using a
hierarchical linear mixed model using experimental
day as a random variable.
2.7. Zebrafish injections
An incross of vhl+/ zebrafish embryos (van Rooijen
et al., 2009) carrying a transgene for GFP-labeled cad-
herin-17 (kidney-specific) at the 1–2 cell stage were
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injected with 1–2 nL of mRNA (concentration
50 nglL1) transcribed from the linearized pCS2+-
TCF21 plasmid (SP6 mMessage mMachine kit;
Ambion, Oudeschoot, the Netherlands) in pure water
with 0.05% Phenol Red using a nanoject2000 microin-
jector (World Precision Instruments, Sarasota, FL,
USA). Pronephros volume (determined by GFP fluo-
rescence) was measured at 5.75 days postfertilization
and imaged with an LSM700 confocal microscope
(Zeiss, Oberkochen, Germany). All embryos were
genotyped after imaging as previously described (van
Rooijen et al., 2009), and only confirmed vhl/
embryos were analyzed. All zebrafish experiments were
approved by the Animal Care Committee of the
University Medical Center Utrecht, the Netherlands.
2.8. Quantitative RT-PCR
Total RNA was extracted and purified using the
RNeasy Mini Kit (74106; QIAGEN, Hilden, Ger-
many). cDNA was synthesized from 1 lg of RNA by
the iScript cDNA Synthesis Kit (170-8891; Bio-Rad)
according to the supplier’s protocol. A cDNA concen-
tration of 5 nglL1 was used for the quantitative RT-
PCRs; samples were run with iQ SYBR Green Super-
mix (170-8880; Bio-Rad) and CFX96 Touch Real-
Time PCR Detection System (Bio-Rad); 95 °C for
3 min, followed by 40 cycles of 10 s of 95 °C, 10 s of
50–65 °C and 20 s of 72 °C, then 10 s at 95 °C fol-
lowed by a melt of the product from 65 to 95 °C.
Values were normalized to the housekeeping gene
GAPDH. All experiments were performed in triplicate
on two different dates, from independent mRNA har-
vests. Relative expression ratios of target genes were
calculated using the comparative cycle threshold
method (Vandesompele et al., 2002). Primer sequences
are provided in Table S1.
2.9. Fluorescence-activated cell sorting (FACS)
We trypsinized cells from each clone and stained
unfixed live cells with anti-E-cadherin (Cat # 563571;
BD Biosciences, Vianen, the Netherlands) and anti-
CD24 (Cat # 562789; BD Biosciences). Ten thousand
events were acquired in a FACSCanto II flow cytome-
ter (BD Biosciences). Representative samples were
plotted as histograms; median fluorescence intensity
(MFI) of each channel was used for quantification.
2.10. Immunofluorescence
Coverslips were seeded with cells at low (50% confluent)
or high density (confluent) and cultured for 24 h with
medium containing serum, followed by 40 h with
serum-free medium. Cells were rinsed with PBS and
fixed with 4% PFA for 15 min at room temperature,
followed by permeabilization with 1% bovine serum
albumin/0.1% Triton X-100 in PBS. Cells were stained
with rabbit anti-E-cadherin (15148, 1 : 500; Abcam) for
4 h at room temperature. Secondary antibody Alexa
Fluor-488 anti-rabbit (1 : 500; Invitrogen) was incu-
bated at room temperature for 1 h. Z-stacks for 10 cells
per condition were generated using a Zeiss LSM700
confocal microscope and photographed using Zeiss Zen
black edition software (Jena, Germany). Maximum pro-
jected images of representative cells are shown.
2.11. Statistical analysis
Statistical analyses were performed by the two-tailed
Student’s t-test using GraphPad, except for statistical
analysis of the real-time migration assay (see para-
graph 2.6.) and analysis of qPCR TCF21 values as
shown in Fig. 1D, which were analyzed using one-way
ANOVA. Differences were considered statistically sig-
nificant at P < 0.05 (*) and P < 0.01 (**).
3. Results
3.1. 786-O ccRCC cells have low endogenous
levels of TCF21
We first asked whether TCF21 methylation (Fig. 1A)
could impact ccRCC cell proliferation. To this end, we
generated isogenic stable cell lines for in vitro compar-
ison of cell proliferation in 786-O cells transfected with
an empty pBABE vector (‘pBABE-mock’ clones
N1F4, B5F1, B6D10, N1G4) and 786-O cells stably
expressing pBABE-TCF21 (clones 2B12, 5D2, 9D12,
9H9). TCF21 mRNA and protein expression is very
low to undetectable in control 786-O cells by qPCR or
by western blot (Fig. S1). Overexpression of TCF21
was examined by qPCR (Fig. 1B) and by western blot
(Fig. 1C, Fig. S1). Treatment of 786-O cells with 3 lM
of the demethylating agent decitabine (5-aza-20-deoxy-
cytidine) for 96 h increased TCF21 mRNA levels
(Fig. 1D), supporting data from Ye et al. (2012) that
the endogenous low level of TCF21 in 786-0 cells can
be at least partly explained by methylation of the
TCF21 promoter.
3.2. TCF21 ectopic expression suppresses
clonogenic cell proliferation
To investigate whether TCF21 expression results in a
reduction in cell proliferation in the context of the
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Fig. 1. TCF21 methylation, expression, and reconstitution. (A) Schematic of the TCF21 gene, showing relative position of the CpG islands to
the first three exons. (B) TCF21 mRNA expression levels in 786-pBABE-mock and 786-O pBABE-TCF21 cells, as measured by qPCR. Data
are presented as mean  SEM. N = 2 independent experiments, each performed in triplicate. (C) Western blots of eight clones of 786-O
that were used for this study; four clones ‘()’ were mock-transfected with pBABE-puro (N1F4, B5F1, B6D10, and N1G4) and four ‘(+)’
were transfected with HA-tagged pBABE-TCF21 (2B12, 5D2, 9D12, and 9H9). Upper blot was immunostained with anti-HA to detect
exogenous TCF21 (18 kDa), while lower blot is loading control stained with anti-actin (42 kDa). N = 2 independent experiments,
representative result shown. (D) Treating 786-O cells with 3 lM decitabine increases the expression of TCF21 mRNA, as measured by
qPCR. N = 1, performed in duplicate. *P < 0.05.
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ccRCC cell line 786-O, we performed standard
growth curves on the four clones that were pBABE-
mock-transfected and compared them to standard
growth curves from the four clones expressing TCF21
after 2, 4, and 5 days. Although the difference in
proliferation was not significant at any of the chosen
time points, we observed a mild trend toward
decreased proliferation in the pBABE-TCF21 clones
(Fig. 2A). We therefore suggest that TCF21 expres-
sion moderately suppressed proliferation of this 786-
O cancer cell line and that the hypothesis that prolif-
eration is suppressed by TCF21 warranted further
investigation.
We next assessed the ability of our clones to gener-
ate colonies from single cells in colony formation
assays. No difference in the overall number of estab-
lished colonies was observed between 786-O pBABE-
mock and 786-O pBABE-TCF21 cells (P > 0.5). How-
ever, individual colonies of 786-O pBABE-mock cells
were larger compared with TCF21-expressing cells
(Fig. 2B,C, P < 0.01). These data are partly consistent
with the proliferation data and support the idea that
while TCF21 overexpression does not seemingly affect
cell survival (colony number), proliferation (colony
size) is suppressed.
3.3. Vhl/ zebrafish pronephros phenotype is
not rescued by TCF21
786-O cells are derived from a ccRCC which, like most
ccRCCs, harbors biallelic somatic mutations of the
von Hippel-Lindau (VHL) tumor suppressor gene
(Gnarra et al., 1994). We have previously generated a
zebrafish model with biallelic constitutive vhl muta-
tions and have reported the embryonic renal pheno-
type as exhibiting an alveolar hyperplastic morphology
(van Rooijen et al., 2011). Not much is known about
the endogenous TCF21 expression in zebrafish
although lineage tracing experiments suggest a role for
TCF21 in epicardial cell fate (Kikuchi et al., 2011).
Given the apparent effect of TCF21 on 786-O vhl/
cells, we questioned whether injection of TCF21 RNA
into our vhl/ zebrafish embryos would partially or
completely rescue the pronephric phenotype. To that
end, 17 vhl/ zebrafish embryos were injected with
human TCF21 RNA (n = 8), or mock-injected with
dye only as a control (n = 9) within an hour after fer-
tilization, and imaged 4 days later, when the prone-
phros phenotype in vhl/ is very clear, with z-stacks
on a confocal microscope. All embryos were geno-
typed for confirmation after the experiment and only
images of confirmed vhl/ were analyzed. No differ-
ences were observed in pronephros size between mock-
injected or TCF21 mRNA-injected zebrafish embryos
(Fig. S2).
3.4. TCF21 expression suppresses migration
Because the effect of the colony formation assays
could only be partially explained by the modest cell
proliferation differences observed in Fig. 2A, we
hypothesized that the colony area differences (Fig. 2C)
might as well be attributed to altered cell migration.
Initial analysis of migration using the chemotaxis-
based Boyden chamber assay on two pBABE-mock
clones (N1G4 and B6D10) and two pBABE-TCF21
clones (5D2 and 9D12) showed a trend toward inhibi-
tion of migration in TCF21-expressing cells (analysis
repeated for N1G4 and 5D2 clones). Fifty-nine percent
fewer of the TCF21-expressing cells migrated on aver-
age (Fig. 3A). To verify these findings, we subse-
quently serum-starved all four pBABE-mock and four
pBABE-TCF21 clones for 24 h and then exposed them
to either empty medium or 10% FBS for each clone in
triplicate and measured impedance changes 12 times
per hour for 24 h using an xCELLigence system. We
observed a decrease in cell migration as represented by
impedance measurements in the isogenic clones
expressing TCF21 (P = 0.0495, Fig. 3B,C). Taken
together, these data indicate that ccRCC cells become
less likely to migrate upon reconstitution of TCF21
expression.
3.5. E-cadherin is upregulated but mislocalized
upon TCF21 expression
Epithelial-to-mesenchymal transition (EMT) is a rever-
sible process by which fully differentiated cells lose
their epithelial features and acquire a migratory mes-
enchymal phenotype, with a concomitant increased
expression of mesenchymal-associated proteins and
decreased expression of epithelial markers. EMT is
known to contribute to the metastasis of RCC
(Mikami et al., 2014), although the underlying cellular
and molecular mechanisms have not been clarified yet.
The inhibition of migration in ccRCC cells by re-
expression of TCF21 (Fig. 3) suggests that TCF21
might function in the renal epithelium by consolidating
epithelial characteristics, or alternatively, in repressing
mesenchymal characteristics. We investigated mes-
enchymal and epithelial marker expression in the eight
786-O clones expressing pBABE-mock versus pBABE-
TCF21 by qPCR. No changes were observed in
mRNA levels of the mesenchymal markers VIM and
snail (SNAI1), but we did observe significant upregula-
tion of epithelial marker E-cadherin (CDH1) both at
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the mRNA and at the protein level in the clones
expressing ectopic TCF21 (Fig. 4A,B). These data
could suggest that cells with hypermethylated TCF21
promoters are more predisposed to EMT, thereby
potentially contributing to the tumor suppressor func-
tion of TCF21 in renal tumors.
Fig. 2. TCF21 expression reduces clonogenic cell proliferation. (A) Pooled data from all four clones either pBABE-mock or pBABE-TCF21 for
cell counts on day 2, 4, or 5 showing an insignificant trend toward lower proliferation in 786-O pBABE-TCF21 cells. Data are presented as
mean  SEM. N = 2 independent experiments, each performed in triplicate. (B) Representative photographs of wells from clonogenic
assays. (C) Quantification of area covered by colonies in clonogenic assays. Data are presented as mean  SEM. N = 5 independent
experiments, each performed in triplicate. **P < 0.01.
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In a melanoma cell line (C8161), re-expression of
TCF21 was described to activate expression of the
metastatic suppressor KISS1 and consequently inhibit
motility of the cells (Arab et al., 2011; Zhang et al.,
2012). We investigated KISS1 expression levels in 786-
O clones expressing pBABE-mock and clones express-
ing pBABE-TCF21; expression levels were unde-
tectably low in both untransfected and transfected
786-O cells, while being robustly expressed in control
human placenta (average Cq value 21.4).
As consistent upregulation of genes involved in the
Sonic hedgehog signaling pathway and Akt cell prolif-
eration pathway has been reported in both CCSKs
and ccRCCs (Cutcliffe et al., 2005; Dormoy et al.,
2009; Guo et al., 2015), we investigated expression of
a few genes involved in these pathways [epidermal
Fig. 3. TCF21 expression reduces migration of cells in vitro. (A) Representative photographs of DAPI-stained nuclei after migration through
a Boyden chamber of 786-O pBABE-mock cells and 786-O pBABE-TCF21 cells. (B) Sample curve of impedance (cell index) from a
representative experiment with all clones over 24 h, from which slopes were calculated. (C) The rate of change in impedance of cells
across a transwell membrane in an XCeLLigence system indicates that clones expressing TCF21 migrate significantly slower than pBABE-
mock-transfected cells. Data are presented as mean  SEM. N = 3 independent experiments; each experiment had four technical
replicates. *P < 0.05.
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growth factor receptor (EGFR), smoothened (SMO),
CCND1] in pBABE-mock and pBABE-TCF21 cells;
no significant difference in expression was observed
(Fig. 4A).
To test the functional relevance of increased CDH1
expression, we performed fluorescence-activated cell
sorting (FACS) of extracellular epithelial differentia-
tion markers CDH1 (E-cadherin) and CD24. Each
786-O clone expressing either pBABE-mock or
pBABE-TCF21 was stained by directly conjugated flu-
orescence antibodies for the endogenous extracellular
epitope of CDH1 or CD24 and sorted on the strength
of the fluorescent signal and side scatter. In contrast
to the qPCR data, we observed no differential CDH1
or CD24 protein expression in the pBABE-TCF21
clones compared to the pBABE-mock clones
(Fig. 4C).
Because the upregulation of CDH1 did not correlate
with increased CDH1 extracellular epitope, we investi-
gated the subcellular localization of E-cadherin using
immunofluorescence. We observed that although
upregulation of E-cadherin is also observed in 786-O
clones expressing ectopic TCF21, it is not localized at
the plasma membrane in correspondingly high levels in
both low-density and confluent cultures (Fig. 4D). We
conclude that TCF21 directly affects expression of
CDH1, although possibly the cancer cell line we used
does not have the intrinsic ability to incorporate signif-
icantly more E-cadherin into the plasma membrane.
Lastly, we examined levels of mesenchymal marker
VIM by western blot and observed that 786-O clones
expressing TCF21 (Fig. S1B) display lower levels of
VIM (Fig. 5).
4. Discussion
In the present study, functional experiments demon-
strate that reconstitution of TCF21 expression in 786-
O cells results in decreased clonogenic proliferation
and suppressed migration in vitro. These data support
a tumor suppressor function for TCF21 in the context
of ccRCC, in accordance with several studies that have
demonstrated that TCF21 acts as a tumor suppressor
gene in different tumor types. For example, re-expres-
sion of TCF21 reduced cell growth and colony forma-
tion in lung cancer cells in vitro and in vivo (Smith
et al., 2006), reduced cell proliferation, promoted
apoptosis and suppressed cell invasion and migration
in colorectal cancer in vitro (Dai et al., 2016), and
reduced cell proliferation and epithelial–mesenchymal
transition in breast cancer cells in vitro (Wang et al.,
2015). In addition, downregulation of TCF21 through
hypermethylation has been reported to be associated
with poor outcome in patients with ccRCC and meta-
static melanoma (Ye et al., 2012).
As reported before, and confirmed in the current
study, expression of TCF21 is (at least partly)
repressed by methylation in 786-O cells (Ye et al.,
2012). TCF21 hypermethylation has also been demon-
strated in other ccRCC cell lines and human ccRCC
tissue samples (Costa et al., 2011; Xin et al., 2016; Ye
et al., 2012). Likewise, in other human cancer types,
such as gastric cancer, colorectal cancer, melanoma,
head and neck cancer, and non-small-cell lung carci-
noma, hypermethylation is described to be the pre-
dominant mechanism for TCF21 downregulation
(Arab et al., 2011; Dai et al., 2016; Smith et al., 2006;
Yang et al., 2015).
To increase metastatic and invasive capacities, can-
cer cells often show loss of epithelial and gain of mes-
enchymal characteristics, which permit invasion along
the basement membrane, establishing an opportunity
for metastasis (Birchmeier et al., 1996; Thiery, 2002).
TCF21 is known to be involved in mesenchymal-to-
epithelial transition (MET) (Acharya et al., 2012;
Quaggin et al., 1999; Smith et al., 2006; Wang et al.,
2015). Although we did not detect decreased mRNA
expression of mesenchymal markers in our 786-O cells
transfected with TCF21, our data support a positive
association of TCF21 expression and increased mRNA
and protein expression of the epithelial marker E-cad-
herin (CDH1), which was markedly upregulated in
Fig. 4. TCF21 expression and regulation of selected epithelial or mesenchymal markers. (A) mRNA expression levels of E-cadherin (CDH1),
SNAI1, SMO, cyclin D1 (CCND1), EGFR, and VIM in 786-O pBABE-mock and 786-O pBABE-TCF21 cells, as measured by qPCR. N = 2
independent experiments; each performed in triplicate. (B) Western blot of E-cadherin and ß-tubulin (loading control) of 786-0 clones
expressing either TCF21 ‘(+)’ or empty vector ‘()’. N = 2 independent experiments. (C) FACS analyses of the eight isogenic clones indicate
no difference in the functional expression of E-cadherin (CDH1) or glycoprotein CD24 in 786-O pBABE-mock cells versus 786-O pBABE-
TCF21 cells. The gray histograms are unstained controls. Next to the histograms are the quantifications of the mean fluorescence intensity
(MFI) for the four clones with pBABE-TCF21 versus pBABE-mock. Data are presented as mean  95% confidence interval. No significant
differences were observed. (D) Confocal maximum projection of E-cadherin (white) in representative 786-0 pBABE-mock (clone B6D10) and
pBABE-TCF21 (clone 9H9) cells, showing minimal changes in expression at the membrane (arrowhead) despite global upregulation in cells
upregulated in cells expressing TCF21. 10 cells imaged per clone. N = nucleus, *P < 0.05, scale bar = 10 lM.
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TCF21-expressing 786-O cells. However, immunofluo-
rescence and FACS experiments demonstrate that
despite global upregulation, expression E-cadherin is
not increased at the plasma membrane, which may be
cell specific for 786-O cells. Inactivation of CDH1 is
described to be prominently associated with tumor
invasiveness, metastatic dissemination, and poor
patient prognosis; the significance of CDH1 expression
for metastatic potential has been shown in a variety of
in vitro and in vivo models (Frixen et al., 1991; Onder
et al., 2008; von Burstin et al., 2009). Therefore,
increase in CDH1 expression might be a possible rea-
son for decreased migration of TCF21-expressing 786-
O cells in the current study, through alternative down-
stream transcriptional pathways, because we did not
detect changes in the extracellular epitope for CDH1
(Canel et al., 2013; Onder et al., 2008). Furthermore,
our results that overexpression of TCF21 inhibits
migration are in accordance with in vitro studies in
colorectal cancer cell lines (Dai et al., 2016, 2017) as
well as siRNA suppression of endogenous TCF21 in
renal progenitor cells which increased migration (Plot-
kin and Mudunuri, 2008). Although re-expression of
TCF21 in melanoma cells and Caki-1 ccRCC cells has
been described to activate expression of the metastatic
suppressor KISS1 (Arab et al., 2011; Zhang et al.,
2012), in the current study KISS1 expression does not
seem to be involved in the suppressed migration of
786-O cells transfected with TCF21. It would also be
of value to explore several recently identified TCF21
targets expressed in renal tubules such as IL6R,
SH2B3, and SMG6 and interrogate their contribution
to phenotypic differences (Sazonova et al., 2015). Fur-
ther studies are warranted to consolidate these data.
Recently, we reported that CCSKs bearing the
BCOR internal tandem duplication showed hyperme-
thylation of TCF21, while CCSKs bearing the translo-
cation t(10;17)(q22;p13) showed significantly lower
methylation levels of the TCF21, suggesting that inter-
nal tandem duplication of BCOR may be directly or
indirectly responsible for TCF21 hypermethylation in
CCSKs (Gooskens et al., 2016). To functionally vali-
date the tumorigenic role of TCF21 hypermethylation
in CCSKs, CCSK models urgently need to be devel-
oped. We explored the possibility of using a vhl/
zebrafish model for reconstitution, but did not observe
any phenotypic modulation. Due to the rarity of
CCSK and limited availability of histologically verified
fresh tissue, it is a challenge to develop such research
tools as cell lines or other CCSK models. If we are
able to develop efficient and physiologically relevant
models through additional studies and could generate
similar results in CCSK cells as in ccRCC cells, then
treatment with demethylating agents might be an
option for these patients. Currently, the most studied
and promising demethylating agents are the DNA
methyltransferase inhibitors decitabine and azacitidine
(Kulis and Esteller, 2010).
5. Conclusions
In summary, our study revealed that restoration of
TCF21 expression in 786-O ccRCC cells results in
decreased clonogenic proliferation and migration.
CCSK models need to be developed to fully determine
the influence of reconstitution of TCF21 expression in
CCSK cells.
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Fig S1. (A) Western blot of anti-TCF21 (18 kDa) on
HEK293T cell lysate (far left, positive control for
endogenous protein), 786-0 parental cells (far right,
negative control), and clones stably transfected with
either empty pBABE-puro plasmid ‘()’, or TCF21
‘(+)’ in pBABE-puro. Equal loading is indicated by b-
tubulin staining (55 kDa). Experiment was performed
twice independently. (B) Western blot of anti-TCF21
(18 kDa) with the same lysates used Fig. 5 shows that
TCF21 was no longer stably expressed in clone 9D12,
which was consequently not loaded on to the blot for
VIM expression (Fig. 5).
Fig. S2. Confocal images of the trunk of vhl/ zeb-
rafish embryos (5 days postfertilization, anterior is to
the left in all images) in a background with green fluo-
rescent pronephros (Tg-cdh17:GFP).
Table S1. Primer sequences used for qPCR experi-
ments.
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